Tesofensine tracker
Educational reference for Tesofensine. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
220 h
Tmax
5 h
Category
other
Also known as: NS2330
> PLACEHOLDER — pending clinical review by licensed pharmacist. Tesofensine is an investigational triple monoamine reuptake inhibitor studied for weight loss. Not FDA-approved. Taken orally.
Mechanism
An investigational small-molecule inhibitor of the reuptake of noradrenaline, dopamine, and serotonin. In research its appetite-suppressant effects are attributed to central monoamine activity.
Research summary
Investigational and not FDA-approved. Originally studied for neurological conditions, it was later evaluated for obesity in phase 2 trials showing weight reduction. Larger confirmatory data and an approved indication are lacking per the literature.
Dosing in the literature
Trials used oral administration under study protocols. There is no approved regimen; this summary does not provide dosing.
Reported side effects
Reported effects include increased heart rate and blood pressure, dry mouth, insomnia, and mood-related effects, reflecting its monoaminergic activity. The full safety profile is not established given its investigational status.
Stacking notes
As an investigational compound, combination use is confined to study settings; interactions with other monoaminergic agents are a significant safety consideration.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Tesofensine phase 2 obesity trial (The Lancet) · The Lancet (2008)search PubMed for tesofensine obesity; investigational
- Monoamine reuptake inhibitor obesity reviews · peer-reviewed review articles (2016)investigational; not FDA-approved
Track Tesofensine in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.